CVS Health stock in focus after Q3 results lift 2026 outlook

CVS Health reported stronger third-quarter operating results on Wednesday, November 4, 2026, and raised several full-year targets. The company said revenue for the three months ended September 30 rose 5.4 percent year over year to 108.4 billion US dollars. The figures were released by CVS Health.

Adjusted earnings per share rose to 2.09 US dollars from 1.60 US dollars in the year-earlier quarter. GAAP diluted earnings per share were 1.68 US dollars, compared with a loss of 3.13 US dollars a year earlier. The prior-year loss included a 5.7 billion US dollar goodwill impairment charge tied to the Health Care Delivery reporting unit, making the GAAP comparison unusually strong.

Insurance margin recovery supports results

CVS Health said adjusted operating income increased 21.2 percent to 4.194 billion US dollars. The Health Care Benefits segment contributed adjusted operating income of 912 million US dollars, compared with 314 million US dollars a year earlier. Its medical benefit ratio improved to 91.3 percent from 92.8 percent, primarily because of better underlying performance in the Government business.

Health Services revenue increased 9.5 percent to 53.964 billion US dollars, while adjusted operating income rose 2.7 percent to 2.106 billion US dollars. Pharmacy drug mix and brand inflation supported revenue, although pharmacy client price improvements limited the operating gain. Pharmacy & Consumer Wellness revenue declined 2.0 percent to 35.498 billion US dollars, but adjusted operating income increased 10.6 percent to 1.635 billion US dollars.

Higher targets, cautious cost outlook

Management raised full-year 2026 adjusted earnings per share guidance to at least 8.20 US dollars from a previous range of 7.90 to 8.10 US dollars. GAAP diluted earnings per share guidance moved to at least 6.98 US dollars from a range of 6.84 to 7.04 US dollars. The company also lifted its cash flow from operations target to at least 15.5 billion US dollars from at least 11.5 billion US dollars and now expects full-year revenue of at least 420 billion US dollars.

The revised outlook reflects higher expectations for the Health Care Benefits and Pharmacy & Consumer Wellness segments. CVS Health nevertheless retained a cautious view for the rest of the year because elevated cost trends and potential macroeconomic headwinds could affect performance.

For investors, the quarter points to a continuing recovery in the insurance margin, while the revenue decline in Pharmacy & Consumer Wellness and pressure from reimbursement and regulatory changes remain operating considerations. The adjusted figures exclude items such as amortization, acquisition-related costs and the 2026 Omnicare guarantee, so they should be read alongside the GAAP result.

CVS Health stock traded at 72.34 euros on Lang & Schwarz at 13:07 CET on Thursday, November 5, 2026. Investors can follow the real-time quote of CVS Health stock.

CVS Health Corp. at a glance

• Company: CVS Health Corp.
• ISIN: US1266501006
• Ticker: CVS
• Home exchange: New York Stock Exchange
• Lang & Schwarz quote: 72.34 euros at 13:07 CET on November 5, 2026
• Third-quarter revenue: 108.4 billion US dollars
• Full-year 2026 adjusted EPS guidance: At least 8.20 US dollars

US healthcare shares remain sensitive to medical cost trends, government program economics and broader market risk appetite. Current S&P 500 market reports provide the wider equity-market context.

More news and analyses on CVS Health stock will follow as the company updates its operating outlook.